STEALTH BIOTHERAPEUTICS CORP (MITO) Fundamental Analysis & Valuation

NASDAQ:MITO • US85789A1051

Current stock price

0.32 USD
0 (-1.36%)
Last:

This MITO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MITO Profitability Analysis

1.1 Basic Checks

  • MITO had negative earnings in the past year.
MITO Yearly Net Income VS EBIT VS OCF VS FCFMITO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -143.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MITO Yearly ROA, ROE, ROICMITO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MITO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MITO Yearly Profit, Operating, Gross MarginsMITO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MITO Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MITO has been increased compared to 1 year ago.
  • The debt/assets ratio for MITO is higher compared to a year ago.
MITO Yearly Shares OutstandingMITO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M
MITO Yearly Total Debt VS Total AssetsMITO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • A Debt/Equity ratio of -0.26 indicates that MITO is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
MITO Yearly LT Debt VS Equity VS FCFMITO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • A Current Ratio of 3.68 indicates that MITO has no problem at all paying its short term obligations.
  • A Quick Ratio of 3.68 indicates that MITO has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68
MITO Yearly Current Assets VS Current LiabilitesMITO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MITO Growth Analysis

3.1 Past

  • MITO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MITO will show a small growth in Earnings Per Share. The EPS will grow by 4.98% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MITO Yearly Revenue VS EstimatesMITO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 5M 10M 15M 20M
MITO Yearly EPS VS EstimatesMITO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. MITO Valuation Analysis

4.1 Price/Earnings Ratio

  • MITO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MITO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MITO Price Earnings VS Forward Price EarningsMITO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.07
MITO Per share dataMITO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.73%
EPS Next 3Y7.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MITO Dividend Analysis

5.1 Amount

  • No dividends for MITO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MITO Fundamentals: All Metrics, Ratios and Statistics

STEALTH BIOTHERAPEUTICS CORP

NASDAQ:MITO (11/15/2022, 8:00:01 PM)

0.32

0 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.54M
Revenue(TTM)N/A
Net Income(TTM)-52.97M
Analysts82.86
Price Target1.81 (465.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.11%
Min EPS beat(2)50.98%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)29.53%
Min EPS beat(4)-47.06%
Max EPS beat(4)63.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.07
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.71
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -143.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z N/A
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.28%
Cap/Depr(5y)39.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16%
OCF growth 3YN/A
OCF growth 5YN/A

STEALTH BIOTHERAPEUTICS CORP / MITO Fundamental Analysis FAQ

What is the fundamental rating for MITO stock?

ChartMill assigns a fundamental rating of 1 / 10 to MITO.


What is the valuation status for MITO stock?

ChartMill assigns a valuation rating of 0 / 10 to STEALTH BIOTHERAPEUTICS CORP (MITO). This can be considered as Overvalued.


What is the profitability of MITO stock?

STEALTH BIOTHERAPEUTICS CORP (MITO) has a profitability rating of 0 / 10.


What is the financial health of STEALTH BIOTHERAPEUTICS CORP (MITO) stock?

The financial health rating of STEALTH BIOTHERAPEUTICS CORP (MITO) is 2 / 10.


What is the earnings growth outlook for STEALTH BIOTHERAPEUTICS CORP?

The Earnings per Share (EPS) of STEALTH BIOTHERAPEUTICS CORP (MITO) is expected to grow by 23.5% in the next year.